Frederick J. Munsch Net Worth

The estimated Net Worth of Frederick Munsch is at least $164 Mille dollars as of 26 February 2022. Mr Munsch owns over 3,330 units of Bausch Health Companies Inc stock worth over $164,272 and over the last 3 years he sold BHC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Munsch BHC stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Bausch Health Companies Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,330 units of BHC stock worth $21,245 on 26 February 2022.

The largest trade he's ever made was exercising 3,330 units of Bausch Health Companies Inc stock on 26 February 2022 worth over $21,245. On average, Mr trades about 833 units every 0 days since 2021. As of 26 February 2022 he still owns at least 25,748 units of Bausch Health Companies Inc stock.

You can see the complete history of Mr Munsch stock trades at the bottom of the page.

Mr. Frederick J. Munsch biography

Frederick J. Munsch is the Controller & Chief Accounting Officer at Bausch Health Companies Inc.

How old is Mr Munsch?

Mr Munsch is 51, he's been the Controller & Chief Accounting Officer of Bausch Health Companies Inc since . There are 19 older and 3 younger executives at Bausch Health Companies Inc. The oldest executive at Bausch Health Companies Inc is Richard De Schutter, 79, who is the Independent Director.

What's Mr Munsch's mailing address?

Frederick's mailing address filed with the SEC is 400 SOMERSET CORPORATE BLVD., , BRIDGEWATER, NJ, 08807.

Insiders trading at Bausch Health Companies Inc

Over the last 6 years, insiders at Bausch Health Companies Inc have traded over $2,786,244 worth of Bausch Health Companies Inc stock and bought 6,317,686 units worth $110,094,785 . The most active insiders traders include John Paulson, Argeris N Karabelas e Brett Icahn. On average, Bausch Health Companies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $824,564. The most recent stock trade was executed by Seana Carson on 5 September 2024, trading 13,370 units of BHC stock currently worth $83,028.

What does Bausch Health Companies Inc do?

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###

Complete history of Mr Munsch stock trades at Bausch Health Companies Inc

Bausch Health Companies Inc executives and stock owners

Bausch Health Companies Inc executives and other stock owners filed with the SEC include:

• Joseph Papa,
  Chairman of the Board, Chief Executive Officer
• Paul Herendeen,
  Chief Financial Officer, Executive Vice President
• Joseph C. Papa,
  CEO & Chairman
• Thomas Appio,
  President & Co-Head Bausch + Lomb/International
• William Humphries,
  
• Christina Ackermann,
  Executive Vice President, General Counsel
• Thomas J. Appio,
  Pres & Co-Head Bausch + Lomb/International
• Paul S. Herendeen,
  Exec. VP and Advisor to Chairman & CEO
• Joseph Gordon,
  President & Co-Head Bausch + Lomb/International
• Christina M. Ackermann,
  Exec. VP, Gen. Counsel & Head of Commercial Operations
• Thomas Ross,
  Lead Independent Director
• Russel Robertson,
  Independent Director
• Robert Power,
  Independent Director
• Argeris Karabelas,
  Independent Director
• Sarah Kavanagh,
  Independent Director
• D. Robert Hale,
  Independent Director
• Amy Wechsler,
  Independent Director
• Richard De Schutter,
  Independent Director
• Andrew Charles von Eschenbach,
  Independent Director
• John Paulson,
  Independent Director
• Tom G. Vadaketh,
  Chief Financial Officer
• Frederick J. Munsch,
  Controller & Chief Accounting Officer
• Kelly Webber,
  Sr. VP & Chief HR Officer
• Stacey Williams,
  VP of Marketing
• Michael McMyne,
  VP of Sales
• Arthur J. Shannon,
  Sr. VP and Head of Investor Relations & Communications
• Dr. Robert F. Butz,
  VP of Medical & Scientific Affairs
• Osama A. Eldessouky,
  CFO & Exec. VP
• Christian A Garcia,
  Director
• Frank D. Lee,
  Director
• Mark C. Mc Kenna,
  President, Salix
• Holdings, L.P.Value Act Hol...,
  
• Brett Icahn,
  Director
• Steven D Miller,
  Director
• Tom George Vadaketh,
  EVP, Chief Financial Officer
• Holdings, L.P.Value Act Cap...,
  
• Aimee J. Lenar,
  EVP, US Pharma
• Seana Carson,
  EVP, General Counsel
• David Robert Value Act Hold...,
  
• Sam Eldessouky,
  EVP & Chief Financial Officer
• Frederick Munsch,
  SVP, Controller and CAO
• Robert Spurr,
  President, U.S. Businesses
• Richard Mulligan,
  Director
• John S Barresi,
  SVP, Controller & CAO
• Jean Jacques Charhon,
  EVP, CFO